Power Stick Deodorant Recall Affects 67,000 Cases Due to FDA Manufacturing Deviations

A recall has been initiated for over 67,000 cases of Power Stick antiperspirant deodorant, impacting products sold at major retailers including Walmart, Dollar Tree, and Amazon. The recall, conducted by A.P. Deauville, LLC, is in response to "cGMP deviations" identified by the Food and Drug Administration (FDA), which pertain to deviations from Current Good Manufacturing Practices. These guidelines are designed to ensure that products are manufactured consistently and in accordance with quality standards.

The recall includes three types of roll-on antiperspirant deodorants: Power Stick for Her Roll-On Antiperspirant Deodorant in "Power Fresh" scent, Power Stick Invisible Protection Roll-On Antiperspirant Deodorant in "Spring Fresh" scent, and Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant. These products are packaged in 1.8 oz/53 mL containers and were distributed nationwide.

The affected Power Stick for Her Roll-On Antiperspirant Deodorant in "Power Fresh" scent involves lot numbers 032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341, and 082826E402. The Power Stick Invisible Protection Roll-On Antiperspirant Deodorant in "Spring Fresh" scent covers lot numbers 031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391, and 111626G231. Finally, the Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant includes lot numbers 101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091, and 111626G221.

In total, the recall involves 21,265 cases of Power Stick for Her Roll-on, 22,482 cases of Power Stick Invisible Protection Roll-On, and 23,467 cases of Power Stick Original Nourishing Invisible Protection deodorants.

The FDA enforcement report highlighted the possible manufacturing issues that led to the recall but did not provide specific details on the nature of the deviations. It is understood that these deviations can emerge at any point during the production process. As of now, the severity classification of the recall remains unspecified by the FDA.

A.P. Deauville, established in Easton, Pennsylvania, operates under FDA regulations and produces a range of personal care products including deodorant, shampoos, conditioners, body washes, and facial wipes. The recall was initiated on July 10, with the company acting voluntarily in response to the FDA's findings.

Despite the recall's expansive scope, further clarification on the specific manufacturing issues remains forthcoming. Analysts predict that this recall could have significant implications for A.P. Deauville's operations depending on the resolution of the identified cGMP deviations.

The recall continues to be tracked, with retailers and consumers being advised to adhere to the guidance set forth by the FDA. Affected products should be returned or disposed of according to the instructions provided by the point of sale. For those seeking more information, direct inquiry with the FDA or A.P. Deauville may provide additional insights into the handling of this recall situation.

This development highlights the critical importance of compliance with manufacturing practices to ensure the safety and efficacy of consumer products. As the recall unfolds, additional updates from the FDA and A.P. Deauville are anticipated, potentially shedding light on the next steps and corrective actions being taken to address the identified issues.